As the brain gets older, the risk of dementia goes up. Changes happen in the brain's structure and function, like cells getting damaged and connections between them weakening. This can cause problems with thinking, memory, and solving problems, which are common in dementia. Many people do not have these problems with age and you can lower your risk of having them with lifestyle and health interventions.
A New Strategy For Creating
Dementia Therapies
For decades large pharmaceutical companies have been focused almost entirely on a single strategy for creating drugs for dementia, removal of toxic proteins from brain cells that build up in the last decades of life.
This is a reactive strategy, waiting until dementia has progressed too far and damage is, in many cases, irreversible. This approach also treats all dementia like a single disease. Not all dementia is the same just like not all breast cancer is the same.
Therapeutic interventions need to begin earlier before irreversible damage to the brain occurs and be tailored to people's individual biomarkers. By tracking people’s brain health and biomarkers earlier in life, we are making preventative therapies a reality.
Our drugs reverse brain aging itself, rather than the late stage toxic proteins that accumulate after damage has irreversibly progressed.
Our AI platform takes a personalized approach based on markers of brain aging to design therapeutics
Traditional method
Most dementia drugs target amyloid plaques, this has been only moderately effective and in some cases drugs have severe side effects. We instead target the program of brain aging.
Neuroage method
We identify genes from people whose brains are aging more slowly. We then design drugs to target the proteins produced by those genes to rejuvenate the brain and treat neurodegenerative diseases.
How We Work
The NeuroAge platform identifies novel drug targets that control the rate of brain aging using large longitudinal and postmortem human brain cohorts. The NeuroAge Test creates one important dataset that we use to created personalized therapies.
Data
We leverage large longitudinal living and postmortem cohorts of human brain data with multi-omics.
Infer
We use AI and causal inference to identify the causal drivers of brain aging.
Personalize
Not all dementia is the same. We tailor drugs for the genetic and molecular makeup of individuals by testing them for their risk factors.
Drug
We design novel drugs for our targets.
Validate
We validate our drugs in human neurons induced directly from fibroblasts, in brain organoids, and in animals.
Test
We run human clinical trials for FDA approval of our drugs for dementia and other age-related neurodegenerative disorders.
Track
We leverage our diagnostic as a biomarker for our clinical trials for faster FDA approval.
